Contents:

ANALGESICS A GLOBAL STRATEGIC BUSINESS REPORT CONTENTS I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS Study Reliability and Reporting Limitations I-1 Disclaimers I-2 Data Interpretation & Reporting Level I-2 Quantitative Techniques & Analytics I-3 Product Definitions and Scope of Study I-3 1. Internal Analgesics I-3 Aspirin I-3 Acetaminophen I-3 Ibuprofen I-4 Others I-4 2. External Analgesics I-4 II. Executive Summary 1. Global Analgesics Market Overview II-1 Pain Therapeutic Market II-1 Analgesics Market - Offering Immense Potential II-1 Internal Analgesics - Riding on a Crest II-1 Liquid Analgesics Register Rapid Growth II-2 Neuropathic Pain- Unexplored II-2 Ibuprofen Scoring High II-2 External Analgesics - In a slump II-2 Boom in Demand for Topical Analgesic Patches II-3 2. Product Overview II-4 A Brief History II-4 Analgesics II-4 Definition II-4 Types of Pain II-4 Acute Pain II-4 Chronic Pain II-5 Drugs Combating Pain II-5 Local Anesthetics II-5 Narcotic Opioids II-5 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) II-6 Types of NSAIDS II-6 Common NSAIDs II-7 Clinical Use... II-7 Side Effects... II-8 Aspirin II-8 The Wonder Drug... II-8 PolyAspirin: The Safer and More Potent Polymer Variant of Aspirin II-9 Mode of Action II-9 Contraindications II-9 Acetaminophen II-9 Acetaminophen Protects Heart Muscle II-10 Acetaminophen Reduces Incidence of Ovarian Cancer II-10 Ibuprofen, Ketoprofen and Naproxen II-10 Combination Analgesics II-10 Table 1: Opioid Analgesics Market: Percentage Share of Opioid / Acetaminophen Combination Products in the Opioid Script Volume (includes corresponding Graph/Chart) II-11 OTC Analgesics: An Overview II-11 3. Industry Dynamics II-12 Escalating R&D Costs: A Boon or Bane? II-12 Timeline of the Drug Approval Process II-12 Cox II Crisis Tarnishes Industry Growth II-12 Novel Therapies to Propel Opioid and Non-Opioid Therapies II-13 Rx-to-OTC Switch II-13 Why Consumers Prefer OTC Drugs? II-13 Development of Analgesic Tripeptides II-13 4. Recent Clinical Trials II-14 PLx Initiates Clinical Trial For Aspirin-PC II-14 Neurodiscovery Receives Approval for NSL-101 Phase II Clinical Trials II-14 5. Product Innovations/Introductions II-15 ProEthic Pharmaceuticals Releases Ibudone for Acute Pain Management II-15 Dr. Reddy’s Laboratories Introduces Supanac for Acute Pain Management II-15 Mallinckrodt Introduces Magnacet™ Tablets for Pain Management II-15 Wockhardt to Launch New Painkiller II-15 Paladin Labs and Labopharm Introduce Tridural™ II-15 Shionogi & Co Introduces OxiNorm Powder 0.5% II-15 McNeil Brings Chewable TYLENOL® GoTabs Tablets II-16 Barr Unveils Generic Version of ACTIQ® II-16 Novartis Launches Voltarol Pain-Eze Emulgel . II-16 TheraQuest Launches TQ-1017 II-16 Mentholatum Company Introduces WellPatch Deep Heat Patch II-16 SSP and Mepha Launch Olfen Patch in Switzerland II-17 W.F. Young Expands Absorbine Jr® II-17 Pfizer Unveils Neurontin II-17 Ligand Pharmaceuticals Introduces Avinza in the US II-17 AlphaRx Introduces Flexogan II-17 Essere Introduces Roll-On Analgesic II-17 Novartis Introduces Topical Analgesic and Cough Suppressant in Sticks II-17 SSL International Introduces Easy-To-Swallow Version of Paramol II-18 Janssen Launches Duragesic, a Narcotic Analgesic II-18 Abbott Laboratories Launches Narcotic Analgesic II-18 Ortho-McNeil Launches Flexeril II-18 Elkins-Sinn Launches Opioid Analgesic II-18 FH Faulding Launches Narcotic Analgesic, Kadian II-18 ICN Pharmaceuticals Launches Opioid Aanalgesic, Levo Dromoran II-18 Amarin Launches Motofen, a Narcotic Analgesic and Anti- Cholinergic II-18 Purdue Pharma Launches MS Contin, a Narcotic Analgesic II-19 Able Laboratories Unveils New Versions of Acetaminophen and Hydrocodone Bitartrate II-19 Whitehall Launches Anadin Analgesic Tablets in South Africa II-19 Leiner Launches Ibuprofen Softgel Capsules II-19 Crookes Healthcare Launches Ibuprofen Singles for Children II-19 SSL International Launches Cuprofen Ibuprofen for Children II-19 Lloydspharmacy Launches Ibuprofen Suspension for Children II-19 6. Recent Industry Activity II-20 Bayer to Acquire Sagmel’s OTC Business II-20 E5 Pharma Receives Approval from FDA II-20 Pharmaceutical Associates Receives Approval from FDA II-20 Concord Receives New Drug Approvals II-20 Hisamitsu Receives Approval for SALONPAsÒ II-20 Johnson & Johnson Submits NDA to FDA II-20 Nycomed and Paladin Inks Joint-Promotion Agreement for Tridural II-20 Akela Extends Agreement with Janssen II-21 Daiichi and Lead Chemical Receives Approval for LoxoninÒ Tape II-21 Tokio Marine Capital to Acquire Showa Yakuhin Kako II-21 Corgenix Collaborates with Randox Laboratories II-21 Corgenix Receives EPO Approval for Aspirin Resistance Method II-21 IOL to Expand Production Capacity II-22 American Oriental Bioengineering Partners with China Aoxing II-22 Abraxis Takes Over Shimoda and its Subsidiary Co. II-22 Ranbaxy Receives Approval from FDA II-22 Wockhardt Receives FDA Approval for DPN + APAP II-22 Alpharma to Market Flector® Patch in the US II-22 Auriga and Mikart Inks Agreement to Market Codein II-22 Watson Receives FDA Approval for Oxycodone Hydrochloride and Ibuprofen II-23 Labopharm’s Tramadol Receives Approval in Canada II-23 Lion Acquires BUFFERIN® Trademark Rights II-23 Grunenthal’s Extends Licensing Agreement with Ortho-McNeil II-23 China Aoxing Pockets LRT II-23 Anesiva Inks Joint Venture Agreement Wanbang II-23 Beijing Med-Pharm Inks Agreement with Lotus Healthcare II-24 LAB International Inks Licensing Agreement with Janssen Pharmaceutica II-24 Three Sixty Pockets Rockford-Montgomery Labs II-24 Antares Enters into License and Development Agreement for Opioid Analgesic II-24 Abraxis BioScience Acquires AstraZeneca’s Analgesic Brand Portfolio II-24 IntelliPharmaCeutics Inks Agreement with Larasan II-24 Ranbaxy and Ethypharm Ink In-licensing Agreement II-25 Elite Collaborates with TPN to Co-develop Analgesic Drug II-25 Novartis Acquires Hexal Company and Major Stake in Eon Labs . II-25 NovaDel Pharma Receives Patent for Buccal Sprays Technology II-25 Auxilium Pharmaceuticals Enters into a Licensing Agreement with PharmaForm II-25 EC Sanctions Sale of Elan’s Prialt II-26 EpiCept Corp. Merges with Maxim Pharmaceuticals, Inc II-26 Reckitt Benckiser plc Acquires Boots Healthcare International II-26 Bayer Acquires Non-prescription Drug Business of Roche II-26 Bextra (Valdecoxib) Receives Green Signal from Health Canada II-27 Rhodia Announces Closure of Acetaminophen Plant in Louisiana II-27 NicOx Re-Gains Rights to CINOD from AstraZeneca II-27 7. Focus on Select Key Players II-28 Bayer Consumer Care (USA) II-28 Bristol-Myers Squibb Company (USA) II-28 Johnson & Johnson (USA) II-28 McNeil Consumer Healthcare (Canada) II-28 Novartis International AG (Switzerland) II-29 Pfizer Inc. (USA) II-29 Reckitt Benckiser Group Plc (UK) II-29 W. F. Young Inc (USA) II-29 Wyeth (USA) II-30 Wyeth Consumer Healthcare II-30 8. Global Market Perspective II-31 Table 2: World Recent Past, Current & Future Analysis for Analgesics by Geographic Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart) II-31 Table 3: World Long-term Projections for Analgesics by Geographic Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) II-32 Table 4: World Historic Review for Analgesics by Geographic Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart) II-33 Table 5: World 15-Year Perspective for Analgesics by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 1998, 2008 & 2012 (includes corresponding Graph/Chart) II-34 Table 6: World Recent Past, Current & Future Analysis for Internal Analgesics by Geographic Region/ Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart) II-35 Table 7: World Long-term Projections for Internal Analgesics by Geographic Region / Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) II-36 Table 8: World Historic Review for Internal Analgesics by Geographic Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart) II-37 Table 9: World 15-Year Perspective for Internal Analgesics by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 1998, 2008 & 2012 (includes corresponding Graph/Chart) II-38 Table 10: World Recent Past, Current & Future Analysis for Internal Analgesics by Product Segment - Aspirin, Acetaminophen, Ibuprofen, and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart) II-39 Table 11: World Long-term Projections for Internal Analgesics by Product Segment - Aspirin, Acetaminophen, Ibuprofen, and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) II-39 Table 12: World Historic Review for Internal Analgesics by Product Segment - Aspirin, Acetaminophen, Ibuprofen, and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart) II-40 Table 13: World 15-Year Perspective for Internal Analgesics by Product Segment - Percentage Breakdown of Dollar Sales for Aspirin, Acetaminophen, Ibuprofen, and Others Markets for Years 1998, 2008 & 2012 (includes corresponding Graph/Chart) II-40 Table 14: World Recent Past, Current & Future Analysis for Aspirin by Geographic Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart) II-41 Table 15: World Long-term Projections for Aspirin by Geographic Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) II-42 Table 16: World Historic Review for Aspirin by Geographic Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart) II-43 Table 17: World 15-Year Perspective for Aspirin by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 1998, 2008 & 2012 (includes corresponding Graph/Chart) II-44 Table 18: World Recent Past, Current & Future Analysis for Acetaminophen by Geographic Region/ Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart) II-45 Table 19: World Long-term Projections for Acetaminophen by Geographic Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) II-46 Table 20: World Historic Review for Acetaminophen by Geographic Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart) II-47 Table 21: World 15-Year Perspective for Acetaminophen by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 1998, 2008 & 2012 (includes corresponding Graph/Chart) II-48 Table 22: World Recent Past, Current & Future Analysis for Ibuprofen by Geographic Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart) II-49 Table 23: World Long-term Projections for Ibuprofen by Geographic Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) II-50 Table 24: World Historic Review for Ibuprofen by Geographic Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart) II-51 Table 25: World 15-Year Perspective for Ibuprofen by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 1998, 2008 & 2012 (includes corresponding Graph/Chart) II-52 Table 26: World Recent Past, Current & Future Analysis for *Other Internal Analgesics by Geographic Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart) II-53 Table 27: World Long-term Projections for *Other Internal Analgesics by Geographic Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) II-54 Table 28: World Historic Review for *Other Internal Analgesics by Geographic Region / Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart) II-55 Table 29: World 15-Year Perspective for *Other Internal Analgesics by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 1998, 2008 & 2012 (includes corresponding Graph/Chart) II-56 Table 30: World Recent Past, Current & Future Analysis for External Analgesics by Geographic Region/ Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 2010 (includes corresponding Graph/Chart) II-57 Table 31: World Long-term Projections for External Analgesics by Geographic Region / Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) II-58 Table 32: World Historic Review for External Analgesics by Geographic Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1991 2000 (includes corresponding Graph/Chart) II-59 Table 33: World 15-Year Perspective for External Analgesics by Geographic Region /Country - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 1998, 2008 & 2012 (includes corresponding Graph/Chart) II-60 III-A. MARKET 1. The United States III-1 A.Market Analysis III-1 Current and Future Analysis III-1 Pain Statistics in the US III-1 Industry Overview III-1 Internal Analgesics III-2 Cox-2 Drugs in for Some Trouble III-2 Switch to OTC Drugs III-2 Table 34: US Internal Tablet Analgesics Market (2007): Percentage Share Breakdown of Leading Ten Brands by Revenues (includes corresponding Graph/Chart) III-2 Table 35: US Internal Liquid Analgesics Market (2007): Percentage Share Breakdown of Leading Ten Brands by Revenues (includes corresponding Graph/Chart) III-3 Table 36: Internal Analgesics Market in the U.S. By Retail Channel (2008E): Percentage Share by Value Sales for Discount Stores, Food / Drug Combination Stores, Chain Drug Stores, Supermarkets, and Independent Drug Stores (includes corresponding Graph/Chart) III-3 Promotional Strategies for the Internal Analgesics III-3 Table 37: Market for Internal Liquid Analgesics in the U.S. by Retail Channel (2008E): Percentage Share by Value Sales for Supermarkets, Drug Stores, and Discounters (includes corresponding Graph/Chart) III-3 Pediatric Analgesics: The New Kid on the Block III-4 External Analgesics III-4 Stretching Boundaries III-4 Table 38: US External Analgesics Market (2007): Percentage Share Breakdown of Leading Ten Brands by Revenues (includes corresponding Graph/Chart) III-4 Table 39: External Analgesics Market in the U.S. By Retail Channel (2008E): Percentage Share by Value Sales for Chain drug stores, Discount stores, Food/drug combination stores, Independent drug stores, and Supermarkets (includes corresponding Graph/Chart) III-4 Rubs, Patches: Driving the External Analgesics Market III-4 Patch Relief Gaining Momentum III-5 Product Innovations/Introductions III-5 Strategic Corporate Developments III-6 Major Players III-9 B.Market Analytics III-11 Table 40: US Recent Past, Current & Future Analysis for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart) III-11 Table 41: US Long-term Projections for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) III-12 Table 42: US Historic Review for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart) III-12 Table 43: US 15-Year Perspective for Analgesics by Product Segment - Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for 1998, 2008 & 2012 (includes corresponding Graph/Chart) III-13 2. Canada III-14 A.Market Analysis III-14 Current and Future Analysis III-14 Key Players III-14 McNeil Consumer Healthcare III-14 Product Launches III-14 Strategic Corporate Developments III-14 B.Market Analytics III-16 Table 44: Canadian Recent Past, Current & Future Analysis for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart) III-16 Table 45: Canadian Long-term Projections for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) III-17 Table 46: Canadian Historic Review for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart) III-17 Table 47: Canadian 15-Year Perspective for Analgesics by Product Segment - Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for 1998, 2008 & 2012 (includes corresponding Graph/Chart) III-18 3. Japan III-19 A.Market Analysis III-19 Current and Future Analysis III-19 Competitive Scenario III-19 Table 48: OTC Analgesics Market in Japan (2005): Market Share of Leading Players by Value - Lion, Arax, Taisho Pharmaceutical, SS Pharmaceutical, Shionogi, and Others (includes corresponding Graph/Chart) III-19 Strategic Corporate Developments III-19 B.Market Analytics III-21 Table 49: Japanese Recent Past, Current & Future Analysis for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart) III-21 Table 50: Japanese Long-term Projections for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) III-22 Table 51: Japanese Historic Review for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart) III-22 Table 52: Japanese 15-Year Perspective for Analgesics by Product Segment - Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for 1998, 2008 & 2012 (includes corresponding Graph/Chart) III-23 4. Europe III-24 A.Market Analysis III-24 Current and Future Analysis III-24 By Product Group/Segment III-24 European Pain Management Market III-24 Generics Restrain Revenue Growth III-24 Table 53: Popular Brands of Pain & Inflammation Medication in Europe (2004): Percentage Share of Aspirin, Voltaren, Ibuprofen, Nurofen, Vioxx, Celebre, Tylenol, Aulin, Anadin, and Paracetamol (includes corresponding Graph/Chart) III-25 B.Market Analytics III-26 Table 54: European Recent Past, Current & Future Analysis for Analgesics by Geographic Region/Country - France, Germany, UK, Italy, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart) III-26 Table 55: European Long-term Projections for Analgesics by Geographic Region/Country - France, Germany, UK, Italy, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) III-26 Table 56: European Recent Past, Current & Future Analysis for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart) III-27 Table 57: European Long-term Projections for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) III-27 Table 58: European Historic Review for Analgesics by Geographic Region/Country - France, Germany, UK, Italy, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart) III-28 Table 59: European Historic Review for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart) III-28 Table 60: European 15-Year Perspective for Analgesics by Geographic Region/Country - Percentage Breakdown of Dollar Sales for France, Germany, UK, Italy, Spain, Russia and Rest of Europe Markets for Years 1998, 2008 & 2012 (includes corresponding Graph/Chart) III-29 Table 61: European 15-Year Perspective for Analgesics by Product Segment - Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for Years 1998, 2008 & 2012 (includes corresponding Graph/Chart) III-30 4a. France III-31 A.Market Analysis III-31 Current and Future Analysis III-31 Competitive Scenario III-31 Table 62: Analgesics Market in France (2005): Market Share of Leading Players by Value - Bristol-Myers Squibb, Therapix, Roche, Bayer Group, Wyeth Consumer Healthcare, and Others) (includes corresponding Graph/Chart) III-31 Key Player III-31 Sanofi Aventis III-31 B.Market Analytics III-32 Table 63: French Recent Past, Current & Future Analysis for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart) III-32 Table 64: French Long-term Projections for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015(includes corresponding Graph/Chart) III-33 Table 65: French Historic Review for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart) III-33 Table 66: French 15-Year Perspective for Analgesics by Product Segment - Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for 1998, 2008 & 2012 (includes corresponding Graph/Chart) III-34 4b. Germany III-35 A.Market Analysis III-35 Current and Future Analysis III-35 Competitive Scenario III-35 Table 67: Analgesics Market in Germany (2005): Market Share of Leading Players by Value - Bayer Group, Boehringer Ingelheim, Wyeth Consumer Healthcare, and Others (includes corresponding Graph/Chart) III-35 B.Market Analytics III-36 Table 68: German Recent Past, Current & Future Analysis for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart) III-36 Table 69: German Long-term Projections for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) III-37 Table 70: German Historic Review for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart) III-37 Table 71: German 15-Year Perspective for Analgesics by Product Segment - Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for 1998, 2008 & 2012 (includes corresponding Graph/Chart) III-38 4c. The United Kingdom III-39 A.Market Analysis III-39 Current and Future Analysis III-39 Key Player III-39 Reckitt Benckiser Group Plc III-39 Competitive Scenario III-39 Table 72: Analgesics Market in the United Kingdom (2005E): Market Shares of Leading Players by Value - Boots Healthcare, GlaxoSmithKline, and Others (includes corresponding Graph/Chart) III-39 Ten Leading Analgesics Brands for Children in the UK Analgesics Market III-39 Strategic Corporate Developments III-39 B.Market Analytics III-40 Table 73: UK Recent Past, Current & Future Analysis for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart) III-40 Table 74: UK Long-term Projections for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015(includes corresponding Graph/Chart) III-41 Table 75: UK Historic Review for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart) III-41 Table 76: UK 15-Year Perspective for Analgesics by Product Segment - Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for 1998, 2008 & 2012 (includes corresponding Graph/Chart) III-42 4d. Italy III-43 A.Market Analysis III-43 Current and Future Analysis III-43 Competitive Scenario III-43 Table 77: Analgesics Market in Italy (2005): Market Share of Leading Players by Value - Bayer Group, Angelini, Novartis, Bristol-Myers Squibb, Boots Healthcare, and Others (includes corresponding Graph/Chart) III-43 B.Market Analytics III-44 Table 78: Italian Recent Past, Current & Future Analysis for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart) III-44 Table 79: Italian Long-term Projections for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) III-45 Table 80: Italian Historic Review for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart) III-45 Table 81: Italian 15-Year Perspective for Analgesics by Product Segment - Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for 1998, 2008 & 2012 (includes corresponding Graph/Chart) III-46 4e. Spain III-47 A.Market Analysis III-47 Current and Future Analysis III-47 Competitive Scenario III-47 Table 82: Analgesics Market in Spain (2005): Market Share of Leading Players by Value - Bayer Group, Boehringer Ingelheim, Bristol-Myers Squibb, Novartis, Boots Healthcare, and Others (includes corresponding Graph/Chart) III-47 B.Market Analytics III-48 Table 83: Spanish Recent Past, Current & Future Analysis for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart) III-48 Table 84: Spanish Long-term Projections for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015(includes corresponding Graph/Chart) III-49 Table 85: Spanish Historic Review for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart) III-49 Table 86: Spanish 15-Year Perspective for Analgesics by Product Segment - Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for 1998, 2008 & 2012 (includes corresponding Graph/Chart) III-50 4f. Rest of Europe III-51 A.Market Analysis III-51 Current and Future Analysis III-51 Product Innovations/Introductions III-51 Strategic Corporate Developments III-51 Key Player III-52 Novartis International AG (Switzerland) III-52 B.Market Analytics III-53 Table 87: Rest of Europe Recent Past, Current & Future Analysis for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart) III-53 Table 88: Rest of Europe Long-term Projections for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) III-54 Table 89: Rest of Europe Historic Review for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart) III-54 Table 90: Rest of Europe 15-Year Perspective for Analgesics by Product Segment - Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for 1998, 2008 & 2012 (includes corresponding Graph/Chart) III-55 5. Asia-Pacific III-56 A.Market Analysis III-56 Current and Future Analysis III-56 The OTC Analgesic Market III-56 OTC Analgesics Market in Asia-Pacific (2004): A Comparative Analysis of the Major Regions - Australia, China and South Korea III-56 Aspirin - The Chinese Market III-56 Strategic Corporate Developments III-57 B.Market Analytics III-58 Table 91: Asia-Pacific Recent Past, Current & Future Analysis for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart) III-58 Table 92: Asia-Pacific Long-term Projections for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) III-59 Table 93: Asia-Pacific Historic Review for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart) III-59 Table 94: Asia-Pacific 15-Year Perspective for Analgesics by Product Segment - Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for 1998, 2008 & 2012 (includes corresponding Graph/Chart) III-60 6. Latin America III-61 A.Market Analysis III-61 Current and Future Analysis III-61 B.Market Analytics III-61 Table 95: Latin American Recent Past, Current & Future Analysis for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart) III-61 Table 96: Latin American Long-term Projections for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) III-62 Table 97: Latin American Historic Review for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart) III-62 Table 98: Latin American 15-Year Perspective for Analgesics by Product Segment - Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for 1998, 2008 & 2012 (includes corresponding Graph/Chart) III-63 7. Rest of World III-64 A.Market Analysis III-64 Current and Future Analysis III-64 Strategic Corporate Developments III-64 B.Market Analytics III-64 Table 99: Rest of World Recent Past, Current & Future Analysis for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart) III-64 Table 100: Rest of World Long-term Projections for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) III-65 Table 101: Rest of World Historic Review for Analgesics by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart) III-65 Table 102: Rest of World 15-Year Perspective for Analgesics by Product Segment - Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for 1998, 2008 & 2012 (includes corresponding Graph/Chart) III-66 III-B. APPENDIX - POPULAR ANALGESIC BRANDS BY REGION Canada III-67 France III-67 Germany III-68 United Kingdom III-69 Leading Analgesics Brands for Children III-70 Italy III-70 Spain III-70 Rest of Europe III-71 Asia-Pacific III-77 Latin America III-81 IV. COMPETITIVE LANDSCAPE

Companies Mentioned

1. 3M Company (USA) 2. 999 Group (China) 3. Abbott Laboratories (USA) 4. Able Laboratories, Inc. (USA) 5. Albemarle Corporation (USA) 6. Alembic Ltd. (India) 7. Aliachem Benelux BV (The Netherlands) 8. Alpharma US Pharmaceuticals (USA) 9. Altana Pharma AG (Germany) 10. Anhui Xinli Pharmaceutical Co., Ltd. (China) 11. Anshan Xianzhen Pharmaceutical Co., Ltd. (China) 12. Apoteket AB (Sweden) 13. AstraZeneca PLC (UK) 14. Athenstaedt GmbH + Co. KG (Germany) 15. Atos Pharmaceuticals & Medical Herbs (Egypt) 16. AWD Pharma GmbH and Co. KG (Dresden) 17. Bard Pharmaceuticals Ltd. (UK) 18. Barr Laboratories, Inc. (USA) 19. Bayer AG (Germany) 20. Beijing Baoshutang Pharmaceutical Co., Ltd. (China) 21. Beijing Shuangqiao Pharmaceutical Co. (China) 22. Beijing Shuguang Pharmaceutical Co., Ltd. (China) 23. Beijing United Pharmaceutical Co., Ltd. (China) 24. Beijing Wanhui Pharmaceutical Group (China) 25. Beijing Zizhu Pharmaceutical Co., Ltd. (China) 26. Belupo Doo (Croatia) 27. Berlin-Chemie AG (Germany) 28. Betapharm Arzneimittel GmbH (Germany) 29. Biological E. Ltd. (India) 30. Biologische Heilmittel Heel GmbH (Germany) 31. Boehringer Ingelheim GmbH (Germany) 32. Boots Group PLC (The) (UK) 33. Bristol-Myers Squibb Co. (USA) 34. C P Pharmaceuticals Ltd. (UK) 35. Cambrex Profarmaco Milano Srl (Italy) 36. Center Laboratories, Inc. (Taiwan) 37. Central Pharmacal Co., Ltd. (The) (Taiwan) 38. Chang An Chemical Ind Co., Ltd. (Taiwan) 39. Changchun Daxing Pharmaceutical Co., Ltd. (China) 40. Chattem, Inc. (USA) 41. Chemferm Industrial Pharmaceuticals SA (Spain) 42. Cheng Fong Chemical Co., Ltd. (Taiwan) 43. Chengdu Pharmaceutical Corporation (China) 44. Chiesi Farmaceutici SpA (Italy) 45. Chifeng Pharmaceutical Group Co., Ltd. (China) 46. Chongqing Daxin Pharmaceutical Co., Ltd. (China) 47. Chongqing Dikang Changjiang Pharmaceutical Co., Ltd. (China) 48. Clonmel Healthcare Ltd. (Ireland) 49. Clover Corporation Limited (Australia) 50. Codal Synto Ltd. (Cyprus) 51. Crookes Healthcare (UK) 52. Cullen & Davison Ltd. (Ireland) 53. Daewoong Pharm Co., Ltd (Korea) 54. Del Laboratories, Inc. (USA) 55. Dompé Farmaceutici SpA (Italy) 56. Douglas Pharmaceuticals Ltd. (New Zealand) 57. Dr. Reddys Laboratories Ltd. (India) 58. DRJ Group, Inc. (USA) 59. Elan Corporation PLC (Ireland) 60. Eli Lilly and Company (USA) 61. Eli Lilly And Company Limited (UK) 62. Elite Pharmaceuticals, Inc. (USA) 63. Endo Pharmaceuticals Holdings, Inc. (USA) 64. F. Hoffmann-La Roche Ltd. (Switzerland) 65. Farmaco SA (Moldova) 66. Farmades SpA (Italy) 67. Farmina Sp. z o.o. (Poland) 68. Foliapharm Gesundheitspflege und Arbeitshygiene GmbH (Germany) 69. Fuzhou Fuxing Pharmaceutical Co., Ltd. (China) 70. Galenika A.D. (Yugoslavia) 71. Gelstat Corporation (USA) 72. Generics [UK] Limited (UK) 73. GlaxoSmithKline PLC (UK) 74. Global Pharmaceutical Industries (Egypt) 75. Gödecke GmbH (Germany) 76. Grunenthal GmbH (Germany) 77. Guangzhou Dongkang Pharmaceutical Co., Ltd. (China) 78. Hainan Sanye Pharmaceutical Co., Ltd. (China) 79. Hainan Xipu Pharmaceutical Co., Ltd. (China) 80. Hakim Pharmaceutical (Iran) 81. Heilongjiang Huaxing Pharmaceutical Co., Ltd. (China) 82. Heilongjiang Jiren Pharmaceutical Co., Ltd. (China) 83. Heinrich Mack Nachf. GmbH & Co. KG (Germany) 84. Helsinn Birex Pharmaceuticals Ltd (China) 85. Henan Huazhong Pharmaceutical Group Corporation (China) 86. Henan Xinxiang Pharmaceutical Co., Ltd. (China) 87. Herron Pharmaceuticals (Australia) 88. Hsin-Kung Pharmaceutical Co., Ltd. (Taiwan) 89. Hunan Pharmaceutical Co., Ltd. (China) 90. Il Yang Pharm Co., Ltd , (Korea) 91. Ildong Pharm Co., Ltd. (Korea) 92. Iran Daru Co. (Iran) 93. Ivax Pharmaceuticals Uk, Ltd (UK). 94. Jiamusi Luling Pharmaceutical Co., Ltd. (China) 95. Jian Yisheng Pharmaceutical Co., Ltd. (China) 96. Jiangsu Diyi Pharmaceutical Co., Ltd. (China) 97. Jiangsu Huatai Antibiotic Co., Ltd. (China) 98. Jiaozuo Kangli Pharmaceutical Co., Ltd. (China) 99. Jinzhou Huaqing Pharmaceutical Co., Ltd. (China) 100. Johnson & Johnson (USA) 101. Kunming Kangfu Pharmaceutical Co., Ltd. (China) 102. Kwangdong Pharmaceutical Co., Ltd. (Korea) 103. Laboratoires Pharmaceutiques Trenker SA (Belgium) 104. Laboratori Guidotti, SpA (Italy) 105. Leiner Health Products, Inc. (USA) 106. Lion Corporation (Japan) 110. Medicis Pharmaceutical Corporation (USA) 111. Medosan Ricerca, SRL (Italy) 112. Merck & Co., Inc. (USA) 113. Mey See Pharmaceutical Co., Ltd. (Taiwan) 114. Milani Leonardo, SRL (Italy) 115. Molimin Arzneimittel GmbH (Germany) 116. Montefarmaco, SpA (Italy) 117. Nang Kuang Pharmaceutical Co., Ltd. (Taiwan) 118. Nanjing Laoshan Pharmaceutical Co., Ltd. (China) 119. Napp Pharmaceuticals Ltd. (UK) 120. Nasr Pharmaceutical & Mfg. (Iran) 121. Naturopathic Laboratories International, Inc. (USA) 122. Nile Pharmaceuticals & Chemical Industries (Egypt) 123. Norma Hellas SA (Greece) 124. North China Pharmaceutical Corporation (China) 125. Novartis AG (Switzerland) 126. Omni Nutraceuticals, Inc. (USA) 127. Perrigo Company (USA) 128. Pfizer, Inc. (USA) 129. Pharma-Cosme (Pvt) Ltd. (Sri Lanka) 130. Pierre Fabre Santi (France) 131. Polfarmex SA (Poland) 132. Prudue Pharma L.P (USA) 133. Qingyuan Xinbeijiang Pharmaceutical Co., Ltd. (China) 134. Ranbaxy Laboratories Ltd. (India) 135. Razak Laboratories (Iran) 136. Reckitt Benckiser PLC (UK) 137. Recordati SpA (Italy) 138. Rhodia SA (France) 139. Rowa Pharmaceuticals, Ltd. (Ireland) 140. Sanofi-Aventis (France) 141. Schering-Plough Corporation (USA) 142. Shandong Ruiyang Pharmaceutical Co., Ltd. (China) 143. Shandong Xinhua Pharmaceutical Co, Ltd. (China) 144. Shanghai Fosun Industrial Co., Ltd. (China) 145. Shanghai Sanwei Pharmaceutical Co., Ltd. (China) 146. Shanghai Siyao Co., Ltd. (China) 147. Shanghai Wuzhou Pharmaceutical Co., Ltd. (China) 148. Shanxi Ruifeng Pharmaceutical Co., Ltd. (China) 149. Shenzhen Gosun Pharmaceutical Co., Ltd. (China) 150. Shenzhen Tongan Pharmaceutical Co., Ltd. (China) 151. Shin poong pharmaceutical co. Ltd (Korea). 152. Shinlon Pharmaceutical Ind Co., Ltd. (Taiwan) 153. Sichuan Chuantou Pharmaceutical Co., Ltd. (China) 154. Sichuan Pharmaceutical Shareholding Co., Ltd. (China) 155. Sigma (Pharmaceutical) Pty., Ltd. (Australia) 156. Sino-America Shanghai Squibb Pharmaceuticals Ltd. (China) 157. Southwest Synthetic Pharmaceutical Corp. Ltd . (China) 158. SSL International PLC (UK) 159. Taejoon Pharmaceutical Co., Ltd. (Korea) 160. Tainan Peng Lai Ent Co., Ltd. (Taiwan) 161. Taiwan Tanabe Seiyaku Co. Ltd. (Taiwan) 162. Taro Consumer Healthcare (USA) 163. Teva Pharmaceutical Industries Ltd. (Israel) 164. The Mentholatum Company, Inc. (USA) 165. Thornton & Ross Ltd. (UK) 166. Tianjin Aikang Medical Health Products Co. (China) 167. Tianjin Lisheng Pharmaceutical Co. Ltd. (China) 168. UCB S.A. (Belgium) 169. Uni-Pharma S.A. (Greece) 170. Vitamed Pharmaceutical Industries Ltd. 171. Vramed Jsc (Bulgaria) 172. Vramed Jsc (Bulgaria) 173. W. F. Young, Inc. (USA) 174. Wanhe Pharmercuetical Co., Ltd. (China) 175. Weleda Ltd . (UK) 176. Wockhardt Limited (India) 177. Wuhan Pharmaceutical Co., Ltd. (China) 178. Wyeth (USA) 179. Xinxiang Zuojinming Pharmaceutical Co., Ltd. (China) 180. YF Chemical Corporation (Taiwan) 181. Zentiva Group (Czech Republic) 182. Zhangjiakou Pharmaceutical Group Corporation (China) 183. Zhejiang Taikang Pharmaceutical Co., Ltd. (China) 184. Zhejiang Yuezhou Pharmaceutical Co., Ltd. (China) 185. Zhengzhou Yuxin Pharmaceutical Co., Ltd. (China) 186. Zhuhai Sez Lizhu Pharmaceutical Group Co., Ltd. (China)